Belgium· BE-AMP-SAM662076-00
Yorvipath 168 µg/0.56 ml
A parathyroid hormones and analogues product containing palopegteriparatide, registered in Belgium by Ascendis Pharma Bone Diseases.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Palopegteriparatide
- Manufacturer
- Ascendis Pharma Bone Diseases
- Country
- Belgium (BE)
- ATC code
- H05AA
- ATC class
- Parathyroid hormones and analogues
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palopegteriparatide in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandYorvipath 168 μg/0.56 ml, Injektionslösung im FertigpenAscendis Pharma Switzerland GmbH
- CzechiaYORVIPATHAscendis Pharma Bone Diseases A/S, Hellerup
- SpainYORVIPATH 168 MICROGRAMOS/0,56 ML SOLUCION INYECTABLE EN PLUMA PRECARGADAAscendis Pharma Bone Diseases A/S
- PolandYorvipathAscendis Pharma Bone Diseases A/S
- SwedenYorvipath 168 mikrogram/0,56 ml Injektionsvätska, lösning i förfylld injektionspennaAscendis Pharma Bone Diseases A/S
- United StatesYorvipathAscendis Pharma, Endocrinology, Inc.
- United KingdomYorvipath 168micrograms/0.56ml solution for injection pre-filled pensAscendis Pharma UK Ltd
- NetherlandsYorvipath 168 microgram/0,56 ml oplossing voor injectie in voorgevulde penAscendis Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Yorvipath
- Liechtenstein · Yorvipath
- Norway · Yorvipath
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ae2519c2-b8fa-4b74-9821-15e2b887f870 GET /v1/drugs/ae2519c2-b8fa-4b74-9821-15e2b887f870?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Yorvipath 168 µg/0.56 ml",
"name_fr": "Yorvipath 168 µg/0.56 ml",
"name_nl": "Yorvipath 168 µg/0.56 ml",
"amp_code": "SAM662076-00",
"strengths": [
"168.0000",
"168.0000",
"168.0000"
],
"pack_count": 2,
"substances": [
"Palopegteriparatide",
"Mannitol",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Parathyroid Hormones and Analogues",
"authorisation_numbers": [
"EU/1/23/1766/001",
"EU/1/23/1766/004"
]
}See everything about palopegteriparatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.